Literature DB >> 15920558

Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis.

Ping L Zhang1, Phillip K Pellitteri, Amy Law, Patricia A Gilroy, G Craig Wood, Thomas L Kennedy, Thomas M Blasick, Mingyue Lun, Conrad Schuerch, Robert E Brown.   

Abstract

Intracellular signals along the epidermal growth factor receptor (EGFR)-Akt-nuclear factor-kappa B (NF-kappaB) pathway have been associated with carcinogenesis in various malignant neoplasms. This investigation was to evaluate the expression of EGFR, phosphorylated(p)-Akt and p-NF-kappaB and correlate them with clinical outcomes in patients with squamous cell carcinoma of the tonsil. A total of 45 patients with squamous cell carcinoma of the tonsil were studied by immunohistochemistry to evaluate the expression levels of EGFR, p-Akt and p-NF-kappaB. Results for squamous cell carcinoma of the tonsil were compared with those for associated high-grade dysplasia and adjacent normal appearing epithelium, when present. In addition, tonsillar epithelium from non-neoplastic specimens of age-matched patients also was stained for the same markers. High-grade dysplasia and squamous cell carcinoma of the tonsil demonstrated a similar pattern of expression, which differed from the pattern seen in the adjacent normal epithelium and tonsillar epithelium from normal controls (an overexpression for each of these three protein analytes in high-grade dysplasia and squamous cell carcinoma of the tonsil as demonstrated by immunohistochemistry). When markers from squamous cell carcinoma of the tonsil were correlated with survival status, only increasing levels of p-NF-kappaB immunoreactivity (a relative overexpression) were statistically significant predictors of poor survival. No markers in squamous cell carcinoma of the tonsil were significantly related to rate of recurrence. When analyzing marker scores from tissue with high-grade dysplasia, relative overexpressions of both p-Akt and p-NF-kappaB were significantly related to poor survival. Additionally, increasing levels of p-NF-kappaB immunopositivity from tissue with high-grade dysplasia were also significantly related to rate of recurrence. In summary, p-NF-kappaB, overexpressed in high-grade dysplasia and squamous cell carcinoma of the tonsil, is associated with worse prognosis in terms of high recurrence and poor survival, respectively. This significant finding in patients with squamous cell carcinoma of the tonsil, in combination with previous animal and in vitro studies, suggests that p-NF-kappaB represents a potential therapeutic target in head and neck squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920558     DOI: 10.1038/modpathol.3800372

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.

Authors:  Ming Yu; Jason Yeh; Carter Van Waes
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

2.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 3.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

4.  Cannabis smoke can be a major risk factor for early-age laryngeal cancer--a molecular signaling-based approach.

Authors:  Sayantan Bhattacharyya; Syamsundar Mandal; Samir Banerjee; Gautam Kumar Mandal; Anup Kumar Bhowmick; Nabendu Murmu
Journal:  Tumour Biol       Date:  2015-03-04

5.  Levels of circulating soluble receptor activator of NF-κB and interleukins-1 predicting outcome of locally advanced basal cell carcinoma.

Authors:  Quan Lin; Yan Li; Duo Zhang; Hongjuan Jin
Journal:  Int J Immunopathol Pharmacol       Date:  2016-10-19       Impact factor: 3.219

6.  Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.

Authors:  Martin Leinung; Daniel Hirth; Aykut Tahtali; Marc Diensthuber; Timo Stöver; Jens Wagenblast
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

7.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.

Authors:  Zhong Chen; Bin Yan; Carter Van Waes
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

8.  Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer.

Authors:  Pattatheyil Arun; Matthew S Brown; Reza Ehsanian; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

9.  Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Authors:  C H Chung; J Aulino; N J Muldowney; H Hatakeyama; J Baumann; B Burkey; J Netterville; R Sinard; W G Yarbrough; A J Cmelak; R J Slebos; Y Shyr; J Parker; J Gilbert; B A Murphy
Journal:  Ann Oncol       Date:  2009-10-22       Impact factor: 32.976

Review 10.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.